- Home
- ESAB vs BLLN Comparison
ESAB vs BLLN Comparison
Compare ESAB & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | BLLN |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ESAB | BLLN |
|---|---|---|
| Price | $64.13 | $101.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $123.64 | ★ $129.00 |
| AVG Volume (30 Days) | ★ 1.1M | 527.4K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | ★ 1.27 | 0.48 |
| Revenue | ★ $2,842,555,000.00 | $305,112,000.00 |
| Revenue This Year | $7.68 | $49.05 |
| Revenue Next Year | $9.40 | $26.16 |
| P/E Ratio | ★ $51.32 | $204.23 |
| Revenue Growth | 3.71 | ★ 99.97 |
| 52 Week Low | $62.74 | $61.96 |
| 52 Week High | $137.42 | $150.44 |
Technical Indicators
Market Signals| Indicator | ESAB | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 48.81 |
| Support Level | $63.79 | $88.85 |
| Resistance Level | $72.65 | $108.50 |
| Average True Range (ATR) | 2.73 | 6.85 |
| MACD | 0.06 | -0.56 |
| Stochastic Oscillator | 11.65 | 40.14 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About BLLN BillionToOne Inc.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.